Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-23
2005-08-23
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S346000, C544S295000, C544S060000, C544S115000, C514S233200, C514S250000
Reexamination Certificate
active
06933294
ABSTRACT:
Compounds having the formula (I),and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, are useful as anti-inflammatory agents, in which R1, R2, and R3are hydrogen, halogen, alkyl, or perfluoroalkyl; R4is an optionally substituted alkyl or cycloalkyl group; X is a linker; A is an aryl, heteroaryl, heterocycle, cycloalkyl, or is absent; and R7is a substituent on A as defined in the specification.
REFERENCES:
patent: 5182386 (1993-01-01), Albaugh et al.
patent: 5306819 (1994-04-01), Albaugh et al.
patent: 5726175 (1998-03-01), Aloup et al.
patent: 573860 (1993-08-01), None
patent: WO 94/05665 (1994-03-01), None
Goldstein et al., “Favorable Effects of Sulfasalazine on Small Bowel Crohn's Disease: A Long-Term Study”,The American Journal of Gastroenterology, vol. 82, No. 9, 1987, pp. 848-853.
Weber et al., “Suppression of NF-kB Activity by Sulfasalazine is Mediated by Direct Inhibition of IkB Kinases α and β”,Gastroenterology, vol. 119, No. 5, pp. 1209-1218.
Asulfidine EN-tabs® sulfasalazine delayed release tablets, USP; Prescribing Information, Pharmacia & Upjohn, Revised Oct. 2000.
R. Bureau, et al., “Conformational Analysis and 3D QSAR Study on Novel Partial Agonists of 5-HT3Receptors”,Quant. Struct.-Act. Relat, vol. 15, pp. 373-381, 1996.
Sylvain Rault et al., “Pyrrolo[1,2-α]thieno[3,2,e]pyrazines”,J. Heterocycl. Chem., vol. 18, pp. 739-742, 1981.
P. Delagrange et al., “Effects of S-21007, a potent 5-HT3partial agonist, in mouse anxiety”,Zhongguo Yaoli Xuebao, vol. 20, pp. 805-812, 1999.
H. Prunier et al., “Synthesis and Biological Evaluation of New Pyrrolothienopyrazine Derivatives as Potential 5-HT4Ligands”,Pharm. Sci., vol. 3, pp. 311-314, 1997.
J. Rouden et al., “Palladium mediated cross-coupling reaction of heteroaryl-imidoyl chloride and primary amines-preparation of a new ligand of serotoninergic receptors”,Tetrahedron Letters, vol. 40, pp. 8109-8112, 1999.
P. Delagrange et al., “Interaction of S 21007 with 5-HT3receptors. In vitro and in vivo characterization”,European Journal of Pharmacology, vol. 316, pp. 195-203, 1996.
I. Baglin et al., “First Tricyclic Oximino Derivatives as 5-HT3Ligands”,Bioorganic&Medicinal Chemistry Letters, vol. 11, pp. 453-457, 2001.
H. Prunier et al., “Novel and Selective Partial Agonists of 5-HT3Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines”,J. Med. Chem., vol. 40, pp. 1808-1819, 1997.
S. Rault et al., “Novel Selective and Partial Agonists of 5-HT3Receptors. Part 1. Synthesis and Biological Evaluation of Piperazinopyrrolothienopyrazines”,J. Med. Chem., vol. 39, pp. 2068-2080, 1996.
R. Bureau et al., “Association of Two 3D QSAR Analyses. Application to the Study of Partial Agonist Serotonin-3 Ligands”,J. Chem. Inf. Comput. Sci. vol. 41, pp. 815-823, 2001.
Beaulieu Francis
Belema Makonen
Bunker Amy
Marinier Anne
Martel Alain
Berch Mark L.
Bristol--Myers Squibb Company
VanAtten Mark K.
LandOfFree
Thiophene-based tricyclic compounds and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiophene-based tricyclic compounds and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiophene-based tricyclic compounds and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3512593